2007 Luminous Award Winners Highlight Ovarian Cancer Treatment and the Importance of Early Detection



    
    German and British reporters named winners of annual Luminous Award
    

    INDIANAPOLIS, Oct. 31 /CNW/ -- One woman's courageous battle to find the
best treatment to fight her ovarian cancer is the subject of the winning entry
in the 2007 Luminous Award.  Launched by Eli Lilly and Company in 2006, the
annual award was created to recognise journalists who bring to light progress
in cancer prevention and treatment and enlighten their audiences through clear
and inspiring reporting.  Winners are selected by an independent panel of
judges from around the world.
    Eli Lilly and Company is proud to present the 2007 Luminous Award to
German journalist Sabine Thor-Wiedemann from the publication Brigitte --
Germany's leading women's magazine.  The award is for her feature entitled
"Survival of the Luckiest," which details a woman's determination to beat the
disease against all odds.  The article also highlights the need for patients
to have access to treatments that meet an international standard.
    Second place in the competition also went to an article focusing on
ovarian cancer.  The award was presented to Simon Crompton of the U.K. from
The Times' health supplement Body & Soul. His article, "The Silent Killer,"
examined the benefit of a simple screening tool and ongoing research that
could lead to early detection, better treatment and improved survival for
thousands of women with ovarian cancer.
    Overall, the winning articles seek to enlighten the public about ovarian
cancer with the hope that increased awareness and screening options will
empower women to take action against this deadly disease.  Even though
survival rates have improved over recent years, less than 40 percent of women
with ovarian cancer survive the first five years after diagnosis, compared
with nearly 80 percent of breast cancer patients.(1)  Although survival
depends on early diagnosis and treatment, ovarian cancer is usually difficult
to detect and as such often arrives unnoticed.
    John Stubbs, chairman of Cancer Voices Australia and spokesperson for the
international Luminous Award judging panel, commented that the standard of the
entries for this year's competition was particularly high.  "Ten finalists
from eight countries highlighted the impact that cancer has on people and
their desire to bring important and significant elements to the public
domain," Stubbs said.  "We congratulate all finalists on their articles and
their dedication to responsible cancer reporting."
    In addition to the global winners, Lilly also presented two Highly
Commended certificates to journalists from Spain and Japan. Spanish journalist
Mayka Sanchez from El Pais, one of Spain's major national newspapers, was
recognized for her article titled "A Very Personal Therapy" outlining the
great importance of molecular diagnosis in cancer and personalized cancer
treatment.  The second Highly Commended certificate went to Japanese
journalist Hidetoshi Oshima from the publication Mainichi Shimbun, for his
article "Drilling Down on Asbestos Issues," which included personal accounts
from people who had lost family members to mesothelioma after working in a
factory, and highlighted the seriousness of asbestos exposure.
    "The Luminous Award has grown into a truly global event, with more than
70 entries received this year from journalists working in 11 countries," said
Garry Nicholson, leader of the Lilly Oncology global brand development team.
"This competition is part of Lilly Oncology's commitment to go beyond medicine
and to provide support in its broadest sense to people with cancer and their
families.  The Luminous Award recognizes journalists who really make a
difference by providing people with quality information and stories of hope
that can inspire and give people with cancer the strength to continue
fighting."
    The independent judging panel for the Luminous Award was comprised of
judges from all over the world and, in addition to Stubbs, chairman of Cancer
Voices Australia, the panel included Jaime G. de la Garza, M.D., research
physician, National Institute of Cancerology, Mexico; Dolores Isla, M.D.,
Lozano Blesa Hospital, Zaragoza, Spain; Viktoria Kun J, award-winning
healthcare journalist with the leading Hungarian national daily newspaper,
Nepszabadsag, Hungary; Takeo Sekihara, board member of the Japanese Cancer
Society, Japan; Nicole Zernik, president of the French Forum of Europa Donna,
the European Breast Cancer Coalition and vice president of the European
Organization, France; and Maggie Hampshire, managing editor, OncoLink, United
States.
    The winner and runner-up of the Luminous Award is given the choice of one
of two prizes; either the opportunity to be enlightened by the work of a
leading oncologist or cancer researcher or a cash donation to be made in the
form of a scholarship in the winner's name, to help a student continue his/her
studies to become a journalist and enlighten others through his/her work.  By
being given the opportunity to either meet a leading oncologist or cancer
researcher, or provide a scholarship, the enlightenment will continue for the
winner and runner-up either personally or through the future work of a student
journalist.
    The international 2007 Luminous Award competition was open to business
reporters or general/consumer journalists reporting for newspapers, magazines,
newsletters, websites and broadcast outlets as well as medical journalists
writing for health, pharmaceutical and medical trade publications.  Entries
are judged on a series of criteria including news value, the ability to
stimulate awareness about advances in oncology prevention and treatment,
effective communication for the intended audience and creativity.
    
    About Lilly Oncology, a Division of Eli Lilly and Company
    
    For more than four decades, Lilly Oncology has been collaborating with
cancer researchers to deliver innovative treatment choices and valuable
programs to patients and physicians worldwide.  Inspired by the courageous
patients living with cancer, Lilly Oncology is providing treatments that are
considered global standards of care and developing a broad portfolio of novel
targeted therapies to accelerate the pace and progress of cancer care.
    
    About Eli Lilly and Company
    
    Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations.   Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs.

    O-LLY

    
    (1) The Office for National Statistics.  One- and five-year survival of
        patients diagnosed between 1996-1999: Major cancers, sex and age,
        England and Wales. Available at www.statistics.gov.uk/  (accessed on
        3 October 2007).
    

    (Logo: http://www.newscom.com/cgi-bin/prnh/20070601/CLF003LOGO )




For further information:

For further information: Amy Sousa of Eli Lilly and Company, 
+1-317-276-8478, sousa_amy_e@lilly.com; or Jean Perkins of CPR Worldwide, +44 
207 395 7035, jean.perkins@fleishmaneurope.com, for Eli Lilly and Company


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890